FTC Redefines Which Drug Patent Deals Need Antitrust OK
The revisions to the commission’s acquisition notification requirements, which will broaden the types of pharmaceutical patent-licensing arrangements that need authorities’ blessing, clarify that even a partial transfer of patent rights can give a licensee the exclusive ability to commercially exploit a drug patent.
The changes have drawn the...
Already a subscriber? Click here to login